


EISAI OPENS NEW PARENTERAL FACILITY IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that construction of a new production facility has been completed in Suzhou, Jiangsu, China.



The new production facility in China

Historically, Eisai has operated its Suzhou Plant for the manufacturing and packaging of solid preparation products for the local market. The establishment of the new facility is aimed at building up the company's local manufacturing capability in order to handle increasing demand in China for its peripheral neuropathy treatment Methycobal[®] injection in expectation of sustained future growth in the market. The move is also expected to promote cost reduction through improving production efficiency in the medium-term.

The new facility was built on an approximately 134,000m² lot in the Suzhou Industrial Park which was newly purchased by Eisai for the construction. It stands two floors aboveground with a total floor space of approximately 3,300m². Serving as the company's new base for parenteral manu